Chiasma Stock Price

0.02 (0.45%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Chiasma Inc CHMA NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.02 0.45% 4.46 4.42 4.69 4.69 4.44 14:18:44
Bid Price Ask Price Spread Spread % News
4.46 4.47 0.01 0.22% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,447 352,266 $ 4.50 $ 1,585,680 1,131,509 2.88 - 7.75
Last Trade Time Type Quantity Stock Price Currency
14:18:44 50 $ 4.47 USD

Chiasma Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 188.71M 42.27M 36.29M $ - $ - -1.10 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 10.00k 0.40%

more financials information »

Chiasma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CHMA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.724.974.404.66424,397-0.26-5.51%
1 Month4.335.004.264.64474,2460.133.0%
3 Months6.307.753.575.37801,012-1.84-29.21%
6 Months4.597.752.885.06554,585-0.13-2.83%
1 Year5.167.752.885.09426,906-0.70-13.57%
3 Years1.859.251.205.21253,1052.61141.08%
5 Years27.0530.521.206.04225,635-22.59-83.51%

Chiasma Description

Chiasma Inc is a biopharmaceutical company that focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Its product candidate includes octreotide capsule which has completed Phase III clinical trial and it is being developed for the potential treatment of acromegaly, a rare, debilitating disease. The company offers its products in the United States and the European Union.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.